Propanc Biopharma (OTC: PPCB) is a clinical stage biopharmaceutical company developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers. Propanc has developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Propanc’s products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, the company intends to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, it intends to develop products to treat early stage cancer, pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit the company’s website at www.propanc.com.
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com
New York, New York